Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.
